RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases

Denosumab in patients with bone metastases from prostate, breast, and other cancers and elevated urinary N-telopeptide (uNTx) during intravenous bisphosphonate (IV BP) therapy: Final results of a randomized, phase II study

(2017) K. Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY

RANKL inhibition in the treatment of bone metastases

(2009) Allan Lipton et al.   Current Opinion in Supportive and Palliative Care

The osteocyte lineage

(2008) Brendon S. Noble   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

(2008) Y.-W. Qiang et al.   BLOOD

Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone

(2008) Mandeep S. Virk et al.   BONE

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

(2008) Allan Lipton et al.   CANCER

Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases

(2008) Kan Yonemori et al.   CANCER SCIENCE

Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation

(2008) Mitsuru Futakuchi et al.   CANCER SCIENCE

Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions

(2008) Robert Coleman et al.   CANCER TREATMENT REVIEWS

Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

(2008) A. Lipton et al.   CLINICAL CANCER RESEARCH

Osteoimmunology: Interactions of the Bone and Immune System

(2008) Joseph Lorenzo et al.   ENDOCRINE REVIEWS

Interleukin-6 Inhibits Receptor Activator of Nuclear Factor κB Ligand-Induced Osteoclastogenesis by Diverting Cells into the Macrophage Lineage: Key Role of Serine727Phosphorylation of Signal Transducer and Activator of Transcription 3

(2008) Laurence Duplomb et al.   ENDOCRINOLOGY

Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL)

(2008) Evangelos Terpos et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*

(2008) Paul J Kostenuik et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

(2008) Georgiana K. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity

(2008) Vera Hirsh et al.   Journal of Thoracic Oncology

RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis

(2008) R. E. Miller et al.   MOLECULAR CANCER THERAPEUTICS

RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model

(2008) K. M. Woods Ignatoski et al.   PROSTATE

RANK ligand as a therapeutic target for bone metastases and multiple myeloma

(2007) G. David Roodman et al.   CANCER TREATMENT REVIEWS